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Abstract
Background: Mammary tumors represent the most common neoplastic disease in female dogs. Recently, the
promoting role of prolactin (PRL) in the development of human breast carcinoma has been shown. Possible
proliferative, anti-apoptotic, migratory and angiogenic effects of PRL on human mammary cancer cells in vitro
and in vivo were suggested. The effects of PRL are mediated by its receptor, and alterations in receptor expression
are likely to play a role in tumor development. Currently, not much data is available about prolactin receptor
(PRLR) expression in canine mammary tumors. To set the basis for investigations on the role of PRL in mammary
tumorigenesis in this species, prolactin receptor expression was evaluated by semi-quantitative real time PCR and
immunohistochemistry on 10 formalin-fixed, paraffin-embedded samples each of canine non-neoplastic mammary
tissue, mammary adenomas and adenocarcinomas.
Results: The highest PRLR expression levels were found in normal mammary tissue, while adenomas, and to
an even higher degree adenocarcinomas, showed a significant decrease in prolactin receptor expression.
Compared to normal tissue, PRLR mRNA was reduced 2.4 fold (p= 0.0261) in adenomas and 4.8 fold (p= 0.008) in
adenocarcinomas. PRLR mRNA expression was significantly lower in malignant than in benign lesions (p= 0.0165).
Immunohistochemistry demonstrated PRLR expression in all three tissue types with signals mostly limited to
epithelial cells.
Conclusions: Malignant transformation of mammary tissue was associated with a decline in prolactin receptor
expression. Further studies are warranted to address the functional significance of this finding.
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Background
Prolactin (PRL) is a polypeptide hormone synthesized
in and secreted by anterior pituitary lactotrophic cells.
In addition, other tissues including the central nervous
system, immune system, uterus and even the mammary
gland are known to produce PRL in humans [1]. In most
mammalian species, PRL is involved in proliferation and
differentiation of normal breast epithelium and in stimu-
lating post partum lactation. The biological actions of
PRL are not limited to its essential role in reproduction,
but also involve regulation of the immune system,
osmotic balance, angiogenesis and behaviour [1]. In the
female dog, as well as in some rodent species, PRL is an
essential luteotrophic hormone in the second half of
pregnancy and is also involved in the display of maternal
behavior [2-4]. PRL plays a promoting role in the
development of human breast carcinoma, in addition to
a variety of benign breast lesions [5-8]. It has been
shown to exert – in an estrogen independent manner –
proliferative, anti-apoptotic, migratory and angiogenic
effects on human mammary cancer cells and tissues
in vitro and in vivo [9]. The effects of PRL are mediated by
its receptor [1]. PRL receptor (PRLR) expression is found
in 70–100% of all mammary tumors and in 93-100% of
normal breast tissue biopsies by means of RT-PCR and
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in-situ hybridization [10-14]. Some studies reported
PRLR expression to be higher in malignant breast lesions
compared to normal tissue [12,15], but others did not
confirm this finding [11,16,17]. In breast cancer cell cul-
ture models, PRLR expression was found to be increased,
decreased or unaltered compared to normal breast epi-
thelium, depending on the cell line used [10,18]. A few
authors described PRLR expression at different subcellu-
lar localizations in normal, benign and malignant breast
epithelial cells: In healthy cells expression seemed to be
limited to the luminal borders, whereas malignant epi-
thelial cells mainly showed cytoplasmatic expression. In
benign lesions, variable degrees of luminal and cytoplas-
matic expression were seen [13,15].
Spontaneously occurring canine mammary tumors show
similar epidemiological, pathological and biochemical
characteristics as human breast cancer, although the rela-
tive frequency of different histological subtypes is very dif-
ferent [19-24]. The incidence in female dogs is threefold
higher than in women, and mammary neoplasms are the
most common tumor type of the intact female dog and
account for approximately 50% of all neoplasms in bitches
[25]. As many as 41-53% of the tumors are malignant, and
in these cases the 2-year survival is only about 25-40%
[25,26]. Incidence increases with age: the median age of
tumor manifestation is 10 to 11 years [27,28]. A variety of
different factors play a role in canine mammary tumori-
genesis, but hormones are, beside age, the most important
[29]. The influence of the sexual steroids estrogen and
progesterone on the pathogenesis of canine mammary
tumors has been studied extensively [23,28-30]. While
steroid hormones are considered to be involved in early
carcinogenesis, they seem to lose their stimulatory effect
during progression of disease [31]. The role of PRL in
tumorigenesis of canine breast cancer is not known to
date. Sporadic publications proposed a tumor-promoting
role [32,33], and presence of PRLR was documented in
canine mammary tumor cells in vivo and in vitro [34,35].
Also were serum and tissue homogenate levels of PRL
found to be elevated in dogs with benign and malignant
mammary tumors [36]. However, data is incomplete,
inconsistent and partially methodologically outmoded.
The aim of this study was to expand our current know-
ledge about the influence of PRL on canine mammary tumo-
rigenesis by evaluating PRLR expression in non-neoplastic
canine mammary tissue and in benign and malignant
mammary tumors by means of semi-quantitative real time
(TaqMan) PCR. Immunohistochemistry was used to iden-
tify the main cells types expressing PRLR in these tissues.
Methods
Tissues
Archival normal and neoplastic mammary tissue that
had been fixed in buffered 10% formalin for 24 to 72 h,
sent to the Institute of Veterinary Pathology, Vetsuisse
Faculty, University of Zurich by the Unit of Small
Animal Reproduction, Vetsuisse Faculty, University of
Zurich, and embedded in paraffin by routine procedures
was used. Selected samples originated from 25 intact
female dogs of different breeds, which had undergone
surgery, consisting either of a regional or a radical mast-
ectomy, due to mammary gland tumor. At the time of
surgery, the dogs were aged between 5 and 13 years.
Any experimental research was approved by the Can-
tonal Veterinary Office of Zurich.
For the present study, ten samples each of normal
mammary tissue, mammary adenomas and mammary
adenocarcinomas, respectively were selected from the
paraffin blocks of the 25 dogs. Selection was based on
state of preservation and histopathological diagnosis.
Two punch biopsies with a diameter of 2.0 mm were
collected manually from each paraffin block at sites
selected using HE stained sections (Tissue MicroArray
Builder, cat no. 20010.2, punch-extractor “pen”, Histo-
pathology Ltd, H-7608 Pécs). Special attention was paid
to removing only the desired tissue type. These two
punch biopsies were embedded side by side in a new
paraffin wax block. From these blocks, the following
consecutive sections were cut using a rotary microtome
(RM 2165, Leica, Germany): 1 × 3 μm section for HE
staining, 20 × 10 μm sections for RNA extraction and
real time PCR (see below), 3 × 3 μm sections for immu-
nohistochemistry (see below), 1 × 3 μm section for HE
staining. The HE stained sections served to make sure
that only the desired tissue type had been harvested; this
staining was done using routine methods.
Semi-quantitative real time (TaqMan) PCR
Excessive paraffin was manually removed using needles
from the sections floating on a water bath before trans-
ferring all sectioned tissue of each block into a 1.5 ml
PCR tube (Eppendorf, Germany). RNA was extracted
using the RNeasy FFPE Kit (Qiagen, Switzerland)
according to the manufacturer’s instructions. RNA con-
centration was measured UV-photometrically (Smart-
Spec, BioRad, Switzerland). RNA was stored at −20°C
until analysis.
RNA was treated with recombinant, RNase-free DNase
I to eliminate genomic DNA contaminations (Roche
Molecular Biochemicals, Mannheim, Germany), accord-
ing to the manufacturer’s instructions. Reverse transcrip-
tion reagents were supplied from Applied Biosystems,
Foster City, CA, USA. Reactions were performed using
random hexamers as primers for the cDNA synthesis.
100 ng of DNase-treated total RNA was used for each
sample. Semi-quantitative Real Time (TaqMan) PCR
was carried out in an automated fluorometer (ABI
PRISMW FAST 7500 Sequence Detection System, Applied
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Biosystems, Foster City, CA, USA) using 96-well optical
plates (Eurogentec, Belgium) according to the previously
described protocol [37,38]. Samples were run in dupli-
cates with Fast Start Universal Probe Master (ROX) from
Roche Diagnostic. In order to make sure that the
reagents used for RT-PCR reactions were not contami-
nated and to confirm the accuracy of the DNase treat-
ment, we used autoclaved water instead of RNA and the
so called RT minus control as negative controls. The
primers as well as the 6-carboxyfluorescein (6-FAM) and
6-carboxytetramethylrhodamine (TAMRA) labeled probes
were ordered from Eurogentec, B-4102 Serain, Belgium.
Selection was done with the aid of the Primer Express
Software (Version 2.0, Applied Biosystems, USA).
Relative quantification was done by normalizing the
signals of the target gene with those of a housekeeping
gene (GAPDH) and using the comparative CT method
(ΔΔ CT method) according to the instructions of the
manufacturer of the ABI PRISMW 7500 Sequence De-
tector and as previously described by Kowalewski et al.
[38]. Data were considered valid if the relative amount
of the reference gene for a sample was constant (i.e. was
similar in both duplicates) and the average amount was
used as a normalization factor in the ΔΔ CT method.
Specificity of selected PCR products was confirmed by
sequencing (Microsynth, Switzerland).
Sequences for primers and TaqMan probes were
as follows:
GAPDH (forward): 5′- GCT GCC AAA TAT GAC
GAC ATC A-3′
GAPDH (reverse): 5′- GTA GCC CAG GAT GCC
TTT GAG-3′
GAPDH (TaqMan Probe): 5′- TCC CTC CGA TGC
CTG CTT CAC TAC CTT-3′
PRLR (forward): 5′- GGA TCT TTG TGG CCG
TTC TTT-3′
PRLR (reverse): 5′- AAG GAT GCA GGT CAC CAT
GCT AT- 3′
PRLR (TaqMan Probe): 5′- ATT ATG GTC GTA GCA
GTG GCT TTG AAA GGC-3′
For statistical data evaluation the software GraphPad
3.06 (GraphPad Software Inc, San Diego, CA, USA) was
used. Due to the uneven distribution of the Real Time
PCR results, the data obtained are presented as geo-
metric means with deviation factor (Xg x DF±1). An
unpaired t-test was performed. P-values< 0.05 were
considered to be significant.
Immunohistochemistry
A standard immunoperoxidase immunohistochemical
procedure was applied as previously described [37-39].
Briefly, from each paraffin block, 3 sections of 3 μm
were cut and mounted on SuperFrost Plus microscope
slides (Menzel-Gläser, Braunschweig, Germany). The
antibody used was goat affinity purified polyclonal anti
human PRLR IgG (R&D Systems, USA) diluted 1:50.
This antibody was chosen after preliminary tests out of a
panel of four antibodies (including the polyclonal H-300
(sc-20992, Sta. Cruz Biotechnology) and the monoclonal
antibodies U5 (SM5033P, Acris, Germany) and B6.2
(AM00543PU-N, Acris, Germany) due to its good signal-
to-background ratio in a tissue array containing canine
non-neoplastic mammary tissues, mammary adenomas
and adenocarcinomas, as well as pituitary tissue. The
other three antibodies were discarded because of less
consistent labeling (U5), complete absence of labeling
(B6.2), or predominance of unspecific labeling (H-300).
Sections incubated without antibody or with the cor-
responding isotype control (irrelevant goat IgG, I-5000,
Vector Laboratories, USA) were used as negative controls.
Evaluation of sections was performed microscopically
at 200x and 400x magnification. Negative controls were
used to differentiate between non-specific or false-
positive staining reactions. Evaluation of PRLR expres-
sion was performed descriptively.
Results
Semi-quantitative real time (TaqMan) PCR
By means of semi-quantitative Real Time PCR, the high-
est PRLR expression levels were observed in non-
neoplastic mammary tissues. In adenomas, expression
was significantly reduced compared to non-neoplastic
tissues (p= 0.026). Adenocarcinomas as well had signifi-
cantly reduced PRLR expression levels compared to
non-neoplastic tissues (p=0.008). PRLR mRNA expres-
sion was significantly lower in adenocarcinomas com-
pared to adenomas (p=0.017). Overall, PRLR expression
was 2.4 fold reduced in adenomas and 4.8 fold reduced in
adenocarcinomas compared to normal tissues (Figure 1).
Immunohistochemistry
Expression of PRLR protein was demonstrated in canine
mammary tumors and in non-neoplastic canine mam-
mary tissues using a polyclonal goat anti human PRLR
antibody (R&D Systems, USA). Specific signal was
detected in non-neoplastic tissues (Figure 2a, b), aden-
omas (Figure 2c-e) and adenocarcinomas (Figure 2f-h).
Non-neoplastic mammary tissues
PRLR positivity was observed in all samples examined in
form of dark brown staining in different compartments
in mammary epithelial cells comprising the cytoplasm
and cell membranes, especially along the luminal and
lateral borders (Figure 2a). In two cases, labeling of the
nuclei was detected. Overall, the signal was very intense
in epithelial cells, while it was mostly absent from
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myoepithelial cells and connective tissue cells. Blood
vessels (endothelial cells and smooth muscle cells) and
inflammatory cells were partly labeled and partly negative.
Secrete in the alveoli was strongly positive in all sections.
Benign lesions: mammary adenomas
All samples showed PRLR positivity. Most samples
showed a slightly less intense labeling than seen in non-
neoplastic mammary gland tissue (Figure 2c). In four
samples, intensity of staining was comparable with nor-
mal tissue. Signals were mainly detected in epithelial
cells and, to a lesser extent, in some myoepithelial cells.
Often, signals were detected at the luminal cell borders
in addition to cytoplasmic labeling (Figure 2c, d). In one
case, labeling was most intense in the basal epithelial
cell cytoplasma, while the luminal epithelial compart-
ments gave weaker signals (Figure 2e). Connective tissue
cells showed slightly more often signals than in non-
neoplastic mammary tissues. Blood vessels were partly
labeled and partly negative, as in non-neoplastic mam-
mary tissues. Some reactivity was also detected in inflam-
matory cells.
Malignant lesions: mammary adenocarcinomas
All examined cases showed PRLR positivity (Figure 2f-h).
Intensity of labeling was in most cases comparable with
benign lesions. Two cases were stained more intensely
than normal tissue. Labeling was most intense in epithe-
lial cells, while only a few signals were detected in the
connective tissue.
Discussion
Our study evaluates for the first time the canine PRLR
expression in non-neoplastic, benign and malignant
canine mammary tissue both at the protein (immunohis-
tochemistry) and the mRNA level (semi-quantitative real
time PCR). Expression was detected in all tissue types,
and expression levels were highest in normal mammary
epithelial tissue, as demonstrated quantitatively by real
time PCR. Moreover, real time PCR showed a significant
reduction in PRLR expression both in benign neoplastic
lesions and even more marked in malignant lesions.
To the authors’ knowledge there are only two other
studies analyzing PRLR expression in canine mammary
tumor cells [34,35]. Rutteman et al. also found reduced
PRLR expression in malignant mammary tumors com-
pared to benign ones [34]. In this study, all cases of nor-
mal tissue and benign lesions were receptor positive, but
positivity was found only in a few malignant lesions [34].
The radioimmunoassay technique used involved binding
of radiolabeled PRL to tissues in order to detect the
presence and quantify the relative expression level of
PRLR. However, in the meantime, modern PCR-based
approaches were shown to be more specific and more
sensitive in human breast cancer studies [40]. Van
Garderen et al. used RT-PCR to demonstrate expression
of PRLR in the canine mammary tumor cell line CMT-
U335 [35]. But the expression rate was not quantitatively
compared to normal canine mammary epithelial cells.
In most studies evaluating human breast cancer, PRLR
expression level in malignant tumors was equal or
decreased compared to benign lesions and normal tissue
[11,13,16,17]. However, a few studies demonstrated a
higher PRLR expression in malignant lesions [12,15].
The heterogeneous subcellular distribution of the PRLR
(variously including cytoplasm, nucleus, sometimes lum-
inal borders of the epithelial cells), labeling of myo-
epithelial cells and weak labeling of individual connective
tissue cells found in our study is in agreement with most
human medicine reports [11,12,16,17,41]. In contrast to
the findings of Gill et al. and Ferreira et al., we were not
able to demonstrate a variation of PRLR expression at
different subcellular locations between non-neoplastic
cells and benign and malignant mammary tumor cells
Figure 1 Expression of PRLR in normal canine mammary tissue, benign (mammary adenomas) and malignant (mammary
adenocarcinomas) lesions as determined by Real Time (TaqMan) RT-PCR (normalized to GAPDH expression): mean (Xg x DF± 1); bars
with one asterisk differ at (P< 0.05); bars with two asterisks differ at (P< 0.01).
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Figure 2 Immunohistochemical labeling of PRLR in canine mammary tissues. a) Non-neoplastic mammary tissue. Signal can be detected in
epithelial cell cytoplasm and in alveolar secrete. Connective tissue cells are mostly negative. b) Non-neoplastic mammary tissue. Epithelial cells are
flattened and exhibit a strong signal. c) Mammary adenoma. The adjacent non-neoplastic tissue shows more intense positive staining than the
neoplastic one. This tissue is from an original block used for the study. d) Mammary adenoma. Signal is present in epithelial cells. e) Mammary
adenoma. Staining is mainly localized to the basal epithelial cell layer. f) Mammary adenocarcinoma. Signal is present in epithelial cells and rarely
in some fibrous tissue cells. g) Mammary adenocarcinoma. An intense signal is present in epithelial cells. h) Mammary adenocarcinoma. Only a
weak signal signal is present in epithelial cells. Immunoperoxidase staining, anti-human PRLR antibody.
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[13,15]. Gill et al. found that PRLR expression was mainly
limited to luminal cell borders in normal female mammary
tissue, while it was both luminal and cytoplasmatic in
benign lesions and mostly cytoplasmatic in malignant
lesions. Ferreira et al. reported similar results in patho-
logical tissues from male individuals. In gynecomastia,
PRLR expression was mainly seen along luminal cell bor-
ders, while in mammary carcinomas from males signals
were mostly cytoplasmatic [13,15]. Similar to others, we
observed staining of endothelial cells and smooth muscle
cells of some intratumoral blood vessels, which might be
related to the angiogenic effect of prolactin [11,17].
Queiroga et al. investigated PRL tissue levels in tissue
homogenates of normal canine mammary tissue, benign
and malignant mammary tumors. They found PRL tissue
levels to be significantly associated with the malignancy
of tumors, with malignant tumors expressing the highest
levels [36]. However, it remains to be demonstrated
whether PRL tissue levels correlate with PRLR status.
Neither PRLR nor possible local PRL expression was
analyzed in this study [36].
A plausible explanation for the fact that PRLR expres-
sion was highest in canine normal mammary tissue and
lowest in malignant tumors is that PRLR expression may
be a differentiation marker of mammary epithelial cells
and that loss of this marker may be a characteristic of
dedifferentiation. While PRL acts as a pro-oncogene in
early neoplastic transformation and is certainly involved
in cellular neoplastic progression and resistance to
breast cancer treatment, it is also well characterized as a
terminal differentiation factor for mammary epithelial
cells and as essential regulator of epithelial plasticity and
invasion and metastasis suppressor hormone [8,9,42-47].
Similarly, steroid hormone receptors are considered cell
differentiation markers as well, and their expression
decreases with increasing malignancy of canine mam-
mary tumors, and is absent in metastases [20]. In this
context, the findings of Queiroga et al. are surprising,
because not only PRL levels, but also steroid hormone
levels were higher in tissue homogenates of malignant
tumors compared to benign lesions and non-neoplastic
tissue [36]. It should be noted, however, that an increase
of the local concentration of hormones does not neces-
sarily need to be associated with increased expression of
their receptors in tumor tissues. Even a very low expres-
sion level of the receptor is sufficient to mediate PRL
responsiveness in human breast cancer cell lines [40].
Furthermore, alterations of intracellular PRL signaling
could be crucially involved in carcinogenesis, as PRL sig-
naling pathways have an essential role in maintaining
physiological cell differentiation and in the regulation of
cell cycle and apoptosis [14,47-49].
Small sample size was the major limitation of this
study. To exclude external variables as well as possible,
only tissue samples from intact female dogs were
included. Unfortunately, it was not possible to retro-
spectively identify the exact stage of estrous cycle in the
bitches due to the lack of a gynecological examination,
vaginal cytology and hormone assays [50]. It seems how-
ever highly unlikely that the mammary tumors used in
this study were removed during estrus, i.e. under estro-
gen influence, because all patients were clinically diag-
nosed as not in heat. Therefore, it cannot be excluded
with certainty that some of the tumors were removed
during metestrus, i.e. under progesterone influence. In
the female pig, only estrogen, but not progesterone alone
or in combination with estrogen has an effect on PRLR
expression [51]. Since the stage of estrous cycle was
not determined in any of the animal or human studies
(analyzing pre-menopausal women) known to the authors,
we consider the data presented in this work to be compar-
able to previous investigations. Another possible limitation
of this study is the fact that we used non-affected mam-
mary tissue from dogs with mammary tumors as normal
samples. Even if this approach is consistent with Rutteman
et al. 1986 [34] and many human studies, which also com-
pared findings in mammary tumors with the findings in
adjacent normal tissue [10-12,14], we cannot completely
exclude genetic or endocrine alterations in our macro-
and microscopically unremarkable samples.
Due to the retrospective nature of our study, we were
not able to evaluate serum PRL levels of the patients.
While previous reports indicated no difference in serum
PRL level between bitches affected by benign or malig-
nant mammary tumors [32,52], a recent study reported
significantly higher serum PRL levels in bitches with
malignant tumors [36]. A prospective study already in
progress will show if female dogs affected by malignant
tumors in fact have increased PRL levels in addition to
decreased tumorous PRLR expression. However, as PRL
serum levels are extremely difficult to compare in small
study populations (pulsatile PRL secretion, massive fluctu-
ation due to season, stage of estrous cycle and individual
influences) and are moreover breed-dependent [2,53-59],
a high patient number is needed to address this question.
Conclusions
In summary, results of our preliminary study show that
PRLR are expressed in canine mammary tumors, and
expression seems to decrease with increasing malignancy.
This finding is new and implicates different hypotheses.
Firstly, decreasing PRLR expression might reflect ded-
ifferentiation of malignant mammary epithelial cells. Sec-
ondly, it is possible that PRL influences canine mammary
tumorigenesis despite decreasing receptor expression, via
alterations in signaling pathways. The importance of PRL
for canine mammary tumor development remains to be
elucidated, and future studies are of interest.
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